A Dose Expansion Study of SX-682 Alone and in Combination with Decitabine in MDS Patients

$4M USD

Funder	NATIONAL CANCER INSTITUTE
Recipient Organization	Syntrix Biosystems, Inc.
Country	United States
Start Date	Sep 16, 2024
End Date	Aug 31, 2025
Duration	349 days
Number of Grantees	2
Roles	Principal Investigator; Co-Investigator
Data Source	NIH (US)
Grant ID	`10922516`

Grant Description

Myelodysplastic syndromes (MDS) are genetically and morphologically diverse hematopoietic neoplasms that arise from a small pool of mutant clones within hematopoietic stem and progenitor compartments [1-9]. MDS is a pre-leukemic syndrome to acute myeloid leukemia (AML). Only four drugs have received regulatory approval

for MDS, with the two hypomethylating agents (HMAs) azacitidine and decitabine (iv and oral with cedazuridine) each with suboptimal response rates (~15-20% for CR+PR) and of limited durability, typically 1-2-years [10]. Once these agents fail, there is no second-line treatment. Prognosis after failure is dismal, with median survival